Journal
AMERICAN JOURNAL OF OPHTHALMOLOGY
Volume 156, Issue 3, Pages 478-486Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2013.05.002
Keywords
-
Categories
Funding
- Abbott GmBH
- Allergan
- Esbatech
- Novartis
- Merck Serono GmBH, Darmstadt, Germany
Ask authors/readers for more resources
PURPOSE: To compare interferon (IFN) beta with methotrexate (MTX) in the treatment of intermediate uveitis with macular edema. DESIGN: Monocentric, prospective, randomized, controlled clinical trial. METHODS: SETTING: Specialized uveitis center at the University of Heidelberg. PATIENT OR STUDY POPULATION: Patients with either primary intermediate uveitis or uveitis associated with multiple sclerosis. MAIN INCLUSION CRITERIA: Visual acuity of 20/30 or worse (0.2 logarithm of the minimal angle of resolution) and macular edema of more than 250 mu m (central 1-mm in optical coherence tomography; Stratus). Randomization into either IFN beta 44 mu g subcutaneously 3 times weekly or 20 mg MTX subcutaneously once weekly. MAIN OUTCOME MEASURES: At 3 months, the primary outcome parameter of mean change in visual acuity was evaluated and efficacy was determined. Secondary parameters were macular edema by optical coherence tomography, inflammatory activity, and retinal sensitivity by microperimetry (MP-1; Nidek). In case of treatment failure, switching to the other treatment arm was possible. RESULTS: Nineteen patients were included. Ten were randomized to MTX, and 9 were randomized to IFN beta. At 3 months, visual acuity improved a mean 0.31 logarithm of the minimal angle of resolution (range, -0.02 to -0.96, 15.6 letters on the Early Treatment Diabetic Retinopathy Study chart) in the IFN beta group versus a mean 0.09 logarithm of the minimal angle of resolution (range, 0.12 to -0.38, 4.7 letters) in the MTX arm (P = .0435, Mann Whitney U test). Macular thickness decreased by a mean of 206 mu m (range, 41 to -416 mu m) in the IFN arm, but increased by 47 (range, 108 to 28 gm) in the MTX group (P < .0001). CONCLUSIONS: Although the sample size is small, results of the trial support superiority of IFN beta over MTX in the treatment of macular edema in the setting of intermediate uveitis ((C) 2013 by Elsevier Inc. All rights reserved.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available